|
|
News Breaks | | | | September 5, 2012 | | 08:17 EDT |  | AMAG | AMAG says Rienso receives Swiss marketing authorization
AMAG Pharmaceuticals announced that the Swiss Agency for Therapeutic Products has granted marketing authorization in Switzerland for ferumoxytol, an intravenous iron therapy to treat iron deficiency anemia in adult patients with chronic kidney disease. Ferumoxytol was approved for the same indication in the European Union in June 2012, and in the United States and Canada under the brand name Feraheme in June 2009 and December 2011, respectively. AMAG’s partner, Takeda Pharmaceutical Company Limited, is responsible for commercialization of ferumoxytol in Switzerland, the EU and Canada, among other territories. Takeda plans to launch ferumoxytol in Switzerland under the brand name Rienso. AMAG is entitled to receive tiered, double-digit royalties on product sales in the licensed territories. AMAG has sole commercial rights for Feraheme in the United States. | |
|
News For AMAG From The Last 14 Days Check below for free stories on AMAG the last two weeks. |
|
|
| May 22, 2013 | | 08:59 EDT | | AMAG | On The Fly: Pre-market Movers
 Subscribe for More Information | | | May 21, 2013 | | 18:56 EDT | | AMAG | On The Fly: After Hours Movers
Subscribe for More Information | | | 17:34 EDT | | AMAG | AMAG says Takeda recalling one batch of Rienso from Swiss market
Subscribe for More Information | | | 08:47 EDT | | AMAG | AMAG Pharmaceuticals Ferumoxytol treatment significant hemoglobin increases
AMAG Pharmaceuticals announced that a new sub-group analysis from IDA-301, a phase III, randomized, placebo-controlled clinical trial, will be presented today at the Digestive Disease Week 2013 meeting in Orlando, Florida. In the full IDA-301 study, 608 adult patients with iron deficiency anemia who had failed or could not tolerate oral iron were treated with ferumoxytol and 200 received placebo. The data from this study showed a direct correlation between a rise in hemoglobin levels and improvements in patients' self-reported measures of fatigue. GI patients with iron deficiency anemia who have not responded well to oral iron supplementation have a need for additional treatment options. The analysis from this study supports the potential of ferumoxytol as a new treatment option for patients with IDA from GI disease who have previously had an unsatisfactory response to oral iron therapy | | | May 15, 2013 | | 09:53 EDT |  | AMAG | AMAG Pharmaceuticals management to meet with Leerink
Subscribe for More Information | |
|
|
|
|
|
|
